Improving the reporting of economic evaluation in osteoporosis: the value of CHEERS 2022 statement

Abstract

Considering the limited availability of healthcare resources alongside major innovations in the management of osteoporosis, economic evaluations have played an increasing role in decision-making. Studies have particularly been conducted to assess the cost-effectiveness of anti-osteoporosis medications [1, 2], fracture liaison services [3], screening strategies [4,5], or to define intervention thresholds [6]. The low quality of input parameters and poor reporting of these economic evaluations may, however, hamper their use by decisionmakers and health professionals.Using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [7] (which was regarded as minimum amount of information required for reporting economic evaluations), in 2015, Hiligsmann et al.[1] assessed the quality of reporting of cost-effectiveness analyses of anti-osteoporosis medications published between 2008 and 2013, revealing that the quality of reporting was largely insufficient for several articles.